CN101272781A - 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途 - Google Patents

新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途 Download PDF

Info

Publication number
CN101272781A
CN101272781A CNA2006800354264A CN200680035426A CN101272781A CN 101272781 A CN101272781 A CN 101272781A CN A2006800354264 A CNA2006800354264 A CN A2006800354264A CN 200680035426 A CN200680035426 A CN 200680035426A CN 101272781 A CN101272781 A CN 101272781A
Authority
CN
China
Prior art keywords
hexane
aza
bicyclo
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800354264A
Other languages
English (en)
Chinese (zh)
Inventor
P·斯科尔尼克
陈正明
A·巴齐尔
J·W·埃普斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DOV Pharmaceutical Inc
Original Assignee
DOV Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DOV Pharmaceutical Inc filed Critical DOV Pharmaceutical Inc
Priority to CN201410309301.2A priority Critical patent/CN104059013B8/zh
Publication of CN101272781A publication Critical patent/CN101272781A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
CNA2006800354264A 2005-07-27 2006-07-25 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途 Pending CN101272781A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410309301.2A CN104059013B8 (zh) 2005-07-27 2006-07-25 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70336405P 2005-07-27 2005-07-27
US60/703,364 2005-07-27
US11/493,431 US20070082940A1 (en) 2005-07-27 2006-07-25 Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US11/493,431 2006-07-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410309301.2A Division CN104059013B8 (zh) 2005-07-27 2006-07-25 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途

Publications (1)

Publication Number Publication Date
CN101272781A true CN101272781A (zh) 2008-09-24

Family

ID=37709141

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410309301.2A Active CN104059013B8 (zh) 2005-07-27 2006-07-25 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
CNA2006800354264A Pending CN101272781A (zh) 2005-07-27 2006-07-25 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410309301.2A Active CN104059013B8 (zh) 2005-07-27 2006-07-25 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途

Country Status (16)

Country Link
US (9) US20070082940A1 (enExample)
EP (2) EP1915146A4 (enExample)
JP (3) JP5184354B2 (enExample)
KR (3) KR101733180B1 (enExample)
CN (2) CN104059013B8 (enExample)
AU (1) AU2006275870B2 (enExample)
BR (1) BRPI0613943B1 (enExample)
CA (1) CA2659215C (enExample)
CY (1) CY1122238T1 (enExample)
IL (2) IL189008A (enExample)
NO (1) NO343037B1 (enExample)
NZ (1) NZ592836A (enExample)
PL (1) PL2719384T3 (enExample)
RU (1) RU2008107336A (enExample)
WO (1) WO2007016155A2 (enExample)
ZA (1) ZA200801825B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029637A (zh) * 2013-12-09 2016-10-12 纽罗万斯公司 新的组合物

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20070082940A1 (en) 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
EP2016053B1 (en) * 2006-04-28 2010-11-10 Merck Sharp & Dohme Corp. Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0716632D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Compounds
GB0716633D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Compounds
GB0804326D0 (en) * 2008-03-07 2008-04-16 Glaxo Group Ltd Novel compounds
ES2421171T3 (es) * 2008-12-16 2013-08-29 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción triples y su uso en métodos
CN102803224A (zh) 2009-06-26 2012-11-28 万能药生物有限公司 新的氮杂双环己烷类化合物
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
LT2819516T (lt) * 2011-07-30 2020-05-25 Otsuka America Pharmaceutical, Inc. (1r,5s)-(+)-1-(naftalen-2-il)-3-azabiciklo{3.1.0} heksano naudojimas monoamino neurotransmiterių paveiktoms ligoms gydyti
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
JP6284140B2 (ja) * 2013-06-17 2018-02-28 株式会社タムラ製作所 Ｇａ２Ｏ３系半導体素子
HUE059348T2 (hu) 2015-06-17 2022-11-28 Otsuka America Pharmaceutical Inc Kristályos vegyületek
WO2018119291A1 (en) * 2016-12-21 2018-06-28 Otsuka America Pharmaceutical, Inc. Synthetic methods
WO2019208807A1 (ja) 2018-04-26 2019-10-31 株式会社エーピーアイ コーポレーション 芳香族ニトリル化合物の製造方法
US12421246B2 (en) * 2019-01-09 2025-09-23 Eisai R&D Management Co., Ltd. Method for synthesis of diazabicyclo[6.2.0]decane related compounds
KR20220083740A (ko) 2019-10-16 2022-06-20 오츠카 세이야쿠 가부시키가이샤 센타나파딘의 제조 방법
CN120842114A (zh) 2019-10-29 2025-10-28 株式会社Api 高纯度2-萘乙腈及其生产方法
WO2022181625A1 (en) 2021-02-23 2022-09-01 Otsuka Pharmaceutical Co., Ltd. Centanafadine pharmaceutical formulations, and methods of making and using same
US20240246914A1 (en) 2021-05-31 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state form of centanafadine hcl and process for preparation thereof
CN117480153A (zh) * 2021-06-15 2024-01-30 大塚制药株式会社 氮杂双环[3.1.0]己烷化合物
US20250375418A1 (en) 2022-09-02 2025-12-11 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (enExample) 1972-04-20 1973-10-23
BE800903A (fr) * 1973-06-14 1973-12-14 Babitsky Boris D Procede d'obtention de polymeres d'alcoyl-2 butadienes-1,3 ou de copolymeres d'alcoyl-2 butadienes-1,3-butadiene-1,3
JPS535994B2 (enExample) * 1974-09-26 1978-03-03
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4196120A (en) * 1975-07-31 1980-04-01 American Cyanamid Company Azabicyclohexanes, method of use and preparation of the same
US4231935A (en) * 1975-07-31 1980-11-04 American Cyanamid Company 1-Phenyl-3-azabicyclo[3.1.0]hexanes
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
GR72713B (enExample) * 1976-09-15 1983-12-01 American Cyanamid Co
US4118417A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
PL120095B2 (en) 1977-10-04 1982-02-27 Univ Lodzki Process for preparing novel derivatives of 1,3,3a,6,7,7a-hexahydrodibenzo-/4,5:8,9/-3a,6-ethenisoindolesagidrodibenzo 4,5:8,9-3a,6-ehtenoizoinidola
CH644580A5 (de) * 1980-01-29 1984-08-15 Hoffmann La Roche Cyclohexen-derivate.
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
US4431661A (en) 1981-08-20 1984-02-14 American Cyanamid Company 5-Aryl-3-azabicyclo[3.2.0]heptan-6-one acetals, and analgesic use therefor
JPS58150526A (ja) * 1982-03-04 1983-09-07 Ube Ind Ltd 光学活性プロパルギルアルコ−ル類およびその製法
EP0100426A1 (en) 1982-07-28 1984-02-15 American Cyanamid Company 3a-(substituted-phenyl)-hexaloctahydro-4,7-alkanoisoindoles
DE3324263A1 (de) * 1983-07-06 1985-01-17 Hoechst Ag, 6230 Frankfurt Derivate der 2-azabicyclo(3.1.0)hexan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-azabicyclo(3.1.0)hexan-derivate als zwischenprodukte und verfahren zu deren herstellung
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5130430A (en) * 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US5204366A (en) 1991-06-10 1993-04-20 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
KR100431038B1 (ko) * 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
ZA969485B (en) * 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US5905154A (en) 1996-06-10 1999-05-18 American Cyanamid Company Process for the preparation of 5-(alkoxymethyl)-2,3-pyridinedicarboximide compounds
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US5911992A (en) * 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia
US6121261A (en) * 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
EP1048653B1 (en) * 1997-12-05 2004-03-03 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US6109269A (en) * 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
ATE404190T1 (de) 2001-12-04 2008-08-15 Schering Corp N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1482921A1 (en) 2002-02-12 2004-12-08 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20040127541A1 (en) * 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation
BR0315433A (pt) * 2002-11-08 2005-08-30 Dov Pharmaceutical Inc Polimorfos de cloridreto de bicifadine
FR2859208B1 (fr) 2003-09-02 2006-01-21 Servier Lab Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2557115C (en) * 2004-02-23 2012-10-02 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
CN101052393A (zh) 2004-08-18 2007-10-10 Dov药物公司 氮杂双环己烷的新型多晶型物
EP1874298A4 (en) 2005-03-08 2009-08-05 Dov Pharmaceutical Inc METHOD AND COMPOSITIONS FOR THE PREPARATION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO [3,1,0] HEXANES
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
US20070082939A1 (en) 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
US20070082940A1 (en) 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
DE602006018152D1 (de) * 2005-08-22 2010-12-23 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3-rezeptoren
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US20090203750A1 (en) 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
EP2016053B1 (en) 2006-04-28 2010-11-10 Merck Sharp & Dohme Corp. Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes
US20080058535A1 (en) 2006-07-25 2008-03-06 Zhengming Chen Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
KR100837555B1 (ko) * 2006-11-24 2008-06-12 동부일렉트로닉스 주식회사 반도체 소자 및 그 제조 방법
EP2167083B1 (en) 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
LT2819516T (lt) 2011-07-30 2020-05-25 Otsuka America Pharmaceutical, Inc. (1r,5s)-(+)-1-(naftalen-2-il)-3-azabiciklo{3.1.0} heksano naudojimas monoamino neurotransmiterių paveiktoms ligoms gydyti
US20140228421A1 (en) 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
EP3530268B1 (en) 2012-10-09 2021-12-15 Attentive Therapeutics, Inc. Therapeutic treatment
AU2014374259A1 (en) 2013-12-09 2016-07-21 Neurovance, Inc. Novel compositions
HUE059348T2 (hu) 2015-06-17 2022-11-28 Otsuka America Pharmaceutical Inc Kristályos vegyületek

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029637A (zh) * 2013-12-09 2016-10-12 纽罗万斯公司 新的组合物

Also Published As

Publication number Publication date
JP2013035842A (ja) 2013-02-21
NO20081016L (no) 2008-04-18
KR20140093750A (ko) 2014-07-28
US8877798B2 (en) 2014-11-04
WO2007016155A2 (en) 2007-02-08
BRPI0613943A2 (pt) 2011-02-22
IL189008A (en) 2017-04-30
ZA200801825B (en) 2009-12-30
JP5184354B2 (ja) 2013-04-17
US20120302619A1 (en) 2012-11-29
RU2008107336A (ru) 2009-09-10
JP5767178B2 (ja) 2015-08-19
KR20170005888A (ko) 2017-01-16
IL245489A0 (en) 2016-06-30
CY1122238T1 (el) 2020-07-31
BRPI0613943B1 (pt) 2021-06-22
PL2719384T3 (pl) 2019-02-28
JP2015134786A (ja) 2015-07-27
CN104059013B8 (zh) 2016-09-21
EP1915146A4 (en) 2010-06-02
US20210023049A1 (en) 2021-01-28
US20130345439A1 (en) 2013-12-26
US20160158197A1 (en) 2016-06-09
EP2719384B1 (en) 2018-08-08
US20180000777A1 (en) 2018-01-04
AU2006275870A1 (en) 2007-02-08
AU2006275870B2 (en) 2013-01-10
US9205074B2 (en) 2015-12-08
KR20080042098A (ko) 2008-05-14
WO2007016155A3 (en) 2007-11-15
NO343037B1 (no) 2018-10-08
US20090233978A1 (en) 2009-09-17
KR101465178B1 (ko) 2014-12-02
IL189008A0 (en) 2008-11-03
US10039746B2 (en) 2018-08-07
US20070082940A1 (en) 2007-04-12
CN104059013A (zh) 2014-09-24
KR101733180B1 (ko) 2017-05-08
NZ592836A (en) 2013-01-25
US20190070148A1 (en) 2019-03-07
CA2659215A1 (en) 2007-02-08
CN104059013B (zh) 2016-06-22
US8461196B2 (en) 2013-06-11
EP1915146A2 (en) 2008-04-30
US20150148399A1 (en) 2015-05-28
CA2659215C (en) 2018-07-10
JP2009502939A (ja) 2009-01-29
EP2719384A1 (en) 2014-04-16
US9737506B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
CN104059013B (zh) 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
JP5301469B2 (ja) Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
EP2167083B1 (en) 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20060223875A1 (en) Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes
HK1122215A (en) Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
HK1196940A (en) Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders
DK2719384T3 (en) Novel preparations with 1-naphthyl-3-azabicyclo [3.1.0] hexanes and use in the treatment of neuropsychiatric disorders.
MX2008001187A (en) Novel 1-aryl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders
HK1196940B (en) Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1122215

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080924